 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H23FN2O |
| Molar mass | 338.426 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5F-SDB-006 is a drug that acts as a potentagonist for thecannabinoid receptors, with an EC50 of 50 nM for human CB1 receptors, and 123 nM for human CB2 receptors.[1] It was discovered during research into the related compoundAPICA which had been sold illicitly as "2NE1".[2] 5F-SDB-006 is the terminally fluorinated analog ofSDB-006, just asSTS-135 is the terminally fluorinated analog ofAPICA. Given the known metabolic liberation (and presence as an impurity) ofamantadine in the related compoundAPINACA, it is suspected that metabolichydrolysis of the amide group of 5F-SDB-006 may releasebenzylamine.
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
